This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amarin: Prepping for FDA Approval Decision

BEDMINSTER, NJ ( TheStreet) -- An Amarin (AMRN) primer ahead of Thursday's expected FDA approval decision for the company's prescription fish-oil pill AMR101:

What time will the FDA decision be announced?

Impossible to say. We may hear in the middle of the day, like we did Friday with Onyx Pharmaceuticals (ONXX), or not until evening as with Vivus (VVUS - Get Report). If you're trading the Amarin approval decision, my best advice is to be ready for news any time after noon EDT. And don't forget that Amarin may decide to halt trading at some point Thursday ahead of the announcement.

Is there a web site I can follow to read about the FDA decision in real time?

The FDA updates its web site with new drug approvals but generally not in real time. Same with FDA's online press room.

Amarin will issue a press release, of course, but I'll be shocked if the company is first out of the gate with the AMR101 news (unless the drug is rejected, which isn't likely.)

Your best bet for instantaneous reporting of the AMR101 decision is Twitter. Log into StockTwits and follow the $AMRN feed. If/when there's real news on AMR101, you'll see it on StockTwits instantaneously. I have a pretty good track record of having a fast draw with FDA drug approval news, so you can follow me on Twitter as well at @adamfeuerstein.

What's the chance that FDA will reject AMR101?

Tiny. I'd give it single-digit odds, certainly no more than that. Investors expect AMR101's approval Thursday by a wide margin -- and rightly so. If FDA rejects AMR101, the outstanding issues are likely to be relatively easy to fix.

Will FDA announce AMR101's New Chemical Entity (NCE) status simultaneously with approval?

Not necessarily. FDA may not make the AMR101 NCE decision public until the Electronic Orange Book (EOB) is next updated, which means Aug. 10.

Amarin has stated previously, however, that FDA may announce its approval decision and NCE status simultaneously. We'll know Thursday.

AMR101? I thought Amarin changed the drug's name to Vascepa?

If we believe the marketing web site leaked Friday, AMR101's new brand name will be Vascepa. Note that Amarin has also trademarked some other possible names, too, including Amracor and Civapri. I'll start referring to AMR101 as Vascepa.

Arena Pharmaceuticals (ARNA - Get Report) and Vivus have both traded lower since their respective drug approvals. Is this what we can also expect from Amarin?

The recent trading pattern for FDA drug approvals (see Arena, Vivus) has been a short-term price spike followed fairly quickly by significant selling/profit taking. With expectations for Vascepa approval so high already, what's preventing Amarin from acting just like Arena and Vivus did?

Here's my prediction (which is probably not worth the electronic ink used to print it): Amarin shares trade up to $18-20 on approval with NCE status still undisclosed but then sell off as investors start wondering about Vascepa's launch. There's more upside in the stock -- and durable -- if approval and NCE status (five years' exclusivity) are granted Thursday, even more if Amarin announces a boffo partnership or takeout in conjunction with Vascepa's approval. Maybe that Pfizer (PFE - Get Report) partnership/takeover rumor is true?!?!?

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARNA $4.19 0.00%
AMRN $1.92 0.00%
GSK $45.26 0.00%
PFE $34.28 0.00%
VVUS $2.53 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs